Compounds > xenocoumacin 2
Page last updated: 2024-11-07

xenocoumacin 2

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

xenocoumacin 2: from Xenorhabdus; RN from Chem Abstr. Index Guide 1991; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID129089
CHEMBL ID522314
MeSH IDM0194790

Synonyms (8)

Synonym
xenocoumacin 2
CHEMBL522314
2,3-dihydroxy-n-[1-(8-hydroxy-1-oxo-3,4-dihydroisochromen-3-yl)-3-methylbutyl]-3-pyrrolidin-2-ylpropanamide
n-(1-(3,4-dihydro-8-hydroxy-1-oxo-1h-2-benzopyran-3-yl)-3-methylbutyl)-alpha,beta-dihydroxy-2-pyrrolidinepropanamide
2-pyrrolidinepropanamide, n-(1-(3,4-dihydro-8-hydroxy-1-oxo-1h-2-benzopyran-3-yl)-3-methylbutyl)-alpha,beta-dihydroxy-
105688-00-4
DTXSID60909681
2,3-dihydroxy-n-[1-(8-hydroxy-1-oxo-3,4-dihydro-1h-2-benzopyran-3-yl)-3-methylbutyl]-3-(pyrrolidin-2-yl)propanimidic acid

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Both compounds exhibit antibacterial activity and potent antiulcer activity against stress-induced ulcers when dosed orally."( Biologically active metabolites from Xenorhabdus spp., Part 2. Benzopyran-1-one derivatives with gastroprotective activity.
Akhurst, RJ; Gregson, RP; Lacey, MJ; McInerney, BV; Taylor, WC, )		0.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (26)

Assay IDTitleYearJournalArticle
AID337413Antimicrobial activity against Corynebacterium xerosis NCTC 9755
AID337410Antimicrobial activity against Pseudomonas aeruginosa 1771P
AID337422Antimicrobial activity against Aspergillus niger at 128 ug/ml after 2 days by tube dilution method
AID337412Antimicrobial activity against Bacillus megaterium NCIB 9376
AID337416Antimicrobial activity against Staphylococcus aureus V573
AID337425Antimicrobial activity against Trichophyton rubrum at 128 ug/ml after 11 days by twofold dilution method
AID337411Antimicrobial activity against Acinetobacter lwoffii BRL 2400
AID337417Antimicrobial activity against Streptococcus pyogenes CN10
AID337418Antimicrobial activity against Streptococcus sanguis ATCC 10556
AID337192Antimicrobial activity against Citrobacter freundii ES
AID337189Antimicrobial activity against Escherichia coli DCO
AID337414Antimicrobial activity against Sarcina lutea ATCC 8740
AID337426Antiulcerogenic activity in stress-induced Wistar rat assessed as protection from ulcer at 25 mg/kg, po
AID337408Antimicrobial activity against Salmonella Typhimurium CT10
AID337420Antimicrobial activity against Candida albicans at 128 ug/ml after 2 days by twofold dilution method
AID337428Antiulcerogenic activity in stress-induced Wistar rat assessed as protection from ulcer at 5 mg/kg, po
AID337427Antiulcerogenic activity in stress-induced Wistar rat assessed as protection from ulcer at 10 mg/kg, po
AID337188Antimicrobial activity against Escherichia coli 10418
AID337423Antimicrobial activity against Aspergillus fumigatus at 128 ug/ml after 2 days by tube dilution method
AID337187Antimicrobial activity against Escherichia coli ESS
AID337409Antimicrobial activity against Proteus mirabilis C977
AID337415Antimicrobial activity against Staphylococcus aureus Oxford NCTC 6571
AID337190Antimicrobial activity against Enterobacter cloacae N1
AID337191Antimicrobial activity against Klebsiella aerogenes A
AID337424Antimicrobial activity against Trichophyton mentagrophytes at 128 ug/ml after 11 days by twofold dilution method
AID337421Antimicrobial activity against Candida parapsilosis at 128 ug/ml after 2 days by twofold dilution method
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (40.00)29.6817
2010's2 (40.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
xenocoumacin 1
xenocoumacin 1: from Xenorhabdus; RN from Chem Abstr. Index Guide 1990; structure given in first source		2.7630
nematophin
nematophin: isolated from Xenorhabdus nematophilus; structure in first source		2.1510indoles
ConditionIndicatedRelationship StrengthStudiesTrials